Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elizabeth Fabre1, Nicola Pécuchet1, Jacques Cadranel2

  • 1INSERM UMR-S1147, université Sorbonne-Paris-Cité, Paris, France; Service d'oncologie médicale, hôpital européen Georges-Pompidou (HEGP), Assistance publique-hôpitaux de Paris, Paris, France.

Bulletin Du Cancer
|January 7, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignore.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

<i>Aspergillus</i> serology for chronic pulmonary aspergillosis diagnosis: optimization of an enzyme-linked immunosorbent assay kit and assessment of a Western blot kit performance.

Journal of clinical microbiology·2026
Same author

Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Cancer cell·2026
Same author

Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studies.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Non-<i>fumigatus Aspergillus</i>-associated pulmonary events: a diagnostic challenge.

Journal of clinical microbiology·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
Same journal

[Robotics in oncological surgery].

Bulletin du cancer·2026
See all related articles

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) are a major advance in treating advanced non-small cell lung cancer. Nivolumab and pembrolizumab show efficacy, with ongoing research into combination therapies.

Area of Science:

  • Oncology
  • Immunology

Background:

  • T-cell-directed therapies represent a significant advancement in treating advanced non-small cell lung cancer (NSCLC).
  • Immune checkpoint inhibitors have demonstrated notable efficacy and improved tolerance in NSCLC patients.

Purpose of the Study:

  • To summarize the clinical development of immune checkpoint inhibitors in advanced non-small cell lung cancer.
  • To highlight the role of programmed cell death protein 1 (PD-1) inhibitors.

Main Methods:

  • Review of clinical trial data for PD-1 inhibitors like nivolumab and pembrolizumab.
  • Analysis of phase III studies evaluating efficacy and tolerance.

Main Results:

  • Nivolumab and pembrolizumab have shown proven efficacy in phase III studies for advanced NSCLC.
Keywords:
Cancer bronchique non àImmunotherapyImmunothérapieNon-small-cell lung cancerPD-1PD-L1petites cellules

Related Experiment Videos

  • Ongoing evaluation of combination therapies and other immune checkpoint inhibitors is underway.

    • Conclusions:

    • Immune checkpoint inhibitors, particularly PD-1 targeting agents, are a cornerstone in advanced NSCLC treatment.
    • Further research is exploring combination strategies to enhance therapeutic benefits.